Amgen is a leading biopharmaceutical company that develops innovative medicines in areas with significant unmet needs. Read ...

A federal judge threw out Amgen’s lawsuit against the state board empowered to set first-in-the-nation price ceilings on prescription drugs in Colorado, finding that the maker of arthritis medication ...

Amgen (AMGN) concluded the recent trading session at $311.55, signifying a +1.5% move from its prior day's close.

Shares of Amgen and IBM are posting strong returns Monday morning, sending the Dow Jones Industrial Average into positive territory. The Dow is trading 113 points (0.3%) higher, as shares of Amgen and ...

TD Cowen analyst Yaron Werber maintained a Buy rating on Amgen (AMGN – Research Report) today and set a price target of $389.00. The company’s ...

Four of the 30 stocks that make up the Dow Jones Industrial Average represent the healthcare sector. Within that group, ...

Amgen had argued the board is unconstitutional because its actions conflict with federal law and would regulate business ...

In the coming two weeks, the FDA is expected to announce three big decisions, including one for a dry eye disease therapy.

Amgen (NASDAQ:AMGN – Get Free Report) was upgraded by research analysts at StockNews.com from a “buy” rating to a “strong-buy ...

Eli Lilly has linked lepodisiran to sustained reductions in a cardiovascular disease risk factor for nearly 1.5 years, bolstering the company’s argument that the siRNA candidate has an edge over ...

Drugs from Novartis, Amgen and now Lilly have proven powerfully effective at reducing Lp(a). Whether that will translate to a ...